Top

Published in:

01-04-2010 | Preclinical study

The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype

Authors: Hany Onsy Habashy, Desmond G. Powe, Emad A. Rakha, Graham Ball, R. Douglas Macmillan, Andrew R. Green, Ian O. Ellis

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Abstract

The transcription functions of oestrogen receptors (ER) are influenced by several coregulators such as PELP1 (proline, glutamate and leucine rich protein 1). The aim of the present study, which uses tissue microarrays and immunohistochemistry, is to explore the clinical and biological relevance of PELP1 protein expression in a large series of consecutive patients (1,162 patients) with invasive breast cancers with particular emphasis on its role in the ER-positive/luminal-like class of tumours. Our results showed that increased PELP1 expression is associated with tumours of larger size, higher histological grade, higher mitotic count, and with positive expression of basal cytokeratins (CK) (CK14; P = 0.018 and CK5/6; P = 0.029), P-cadherin (P = 0.002), p53 and MIB1 (P = 0.018). There was an inverse association between PELP1 expression and ER (P = 0.002), progesterone (PgR) (P = 0.004), androgen (AR) receptor (P < 0.001), and luminal CK (CK18; P = 0.027) expression. A significant association between PELP1 expression and shorter breast cancer specific survival (BCSS) (P = 0.002) and disease-free survival (DFI) (P = 0.006) was found. Multivariate Cox hazard analysis showed that PELP1 expression was an independent predictor of shorter BCSS (Hazard ratio (HR) = 1.349, P = 0.006) and shorter DFI (HR = 1.255, P = 0.011). In the ER-positive/luminal-like group (n = 768), PELP1 expression showed similar association with other clinicopathological variables and was an independent predictor of shorter DFI (HR = 1.256, P = 0.036). In conclusion, PELP1 protein expression is an independent prognostic predictor of shorter BCSS and DFI in breast cancer and its elevated expression is positively associated with markers of poor outcome. PELP1 appears to have a potential application in assessing the clinical outcome of patients with ER-positive breast cancer.

Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A et al (2001) Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 276:38272–38279PubMed

Brann DW, Zhang QG, Wang RM, Mahesh VB, Vadlamudi RK (2008) PELP1—a novel estrogen receptor-interacting protein. Mol Cell Endocrinol 290:2–7. doi:10.1016/j.mce.2008.04.019 CrossRefPubMed

Rajhans R, Nair HB, Nair SS, Cortez V, Ikuko K, Kirma NB et al (2008) Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol 22:649–664. doi:10.1210/me.2007-0350 CrossRefPubMed

Nagpal JK, Nair S, Chakravarty D, Rajhans R, Pothana S, Brann DW et al (2008) Growth factor regulation of estrogen receptor coregulator PELP1 functions via protein kinase a pathway. Mol Cancer Res 6:851–861. doi:10.1158/1541-7786.mcr-07-2030 CrossRefPubMed

Choi YB, Ko JK, Shin J (2004) The transcriptional corepressor, PELP1, recruits HDAC2 and masks histones using two separate domains. J Biol Chem 279:50930–50941. doi:10.1074/jbc.M406831200 CrossRefPubMed

Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK (2004) Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 64:6416–6423. doi:10.1158/0008-5472.can-04-1786 CrossRefPubMed

Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK (2007) Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 67:5505–5512. doi:10.1158/0008-5472.can-06-3647 CrossRefPubMed

Tzelepi V, Grivas P, Kefalopoulou Z, Kalofonos H, Varakis J, Sotiropoulou-Bonikou G (2009) Expression of estrogen receptor co-regulators NCoR and PELP1 in epithelial cells and myofibroblasts of colorectal carcinomas: cytoplasmic translocation of NCoR in epithelial cells correlates with worse prognosis. Virchows Arch 454(1):41–53. doi:10.1007/s00428-008-0708-4 CrossRefPubMed

Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350. doi:10.1002/ijc.21004 CrossRefPubMed

10.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast-cancer. 1. The value of histological grade in breast-cancer—experience from a large study with long-term follow-up. Histopathology 19:403–410. doi:10.1111/j.1365-2559.1991.tb00229.x CrossRefPubMed

11.

Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast-cancer. Breast Cancer Res Treat 22:207–219. doi:10.1007/BF01840834 CrossRefPubMed

12.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J et al (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44:1541–1551. doi:10.1016/j.ejca.2008.04.020 CrossRefPubMed

13.

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR et al (2009) Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer ResTreat. doi:10.1007/s10549-009-0345-x

14.

McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS (1985) Estrogen-receptor analyses—correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721PubMed

15.

Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259. doi:10.1158/1078-0432.ccr-04-0713 CrossRefPubMed

16.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310. doi:10.1158/1078-0432.ccr-08-2132 CrossRefPubMed

17.

Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG et al (2006) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26:1507–1516. doi:10.1038/sj.onc.1209920 CrossRefPubMed

18.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093 CrossRefPubMed

19.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMed

20.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423. doi:10.1073/pnas.0932692100 CrossRefPubMed

21.

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398. doi:10.1073/pnas.1732912100 CrossRefPubMed

22.

West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R et al (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462–11467. doi:10.1073/pnas.201162998 CrossRefPubMed

23.

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009. doi:10.1056/NEJMoa021967 CrossRefPubMed

24.

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a CrossRefPubMed

25.

Nair S, Vadlamudi RK (2007) Emerging significance of ER-coregulator PELP1/MNAR in cancer. Histol Histopathol 22:91–96PubMed

26.

Stallcup MR, Kim JH, Teyssier C, Lee Y-H, Ma H, Chen D (2003) The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J Steroid Biochem Mol Biol 85:139–145. doi:10.1016/S0960-0760(03)00222-X CrossRefPubMed

27.

Frietze S, Lupien M, Silver PA, Brown M (2008) CARM1 Regulates Estrogen-Stimulated Breast Cancer Growth through Up-regulation of E2F1. Cancer Res 68:301–306. doi:10.1158/0008-5472.can-07-1983 CrossRefPubMed

28.

Schiff R, Massarweh S, Shou J, Bharwani L, Arpino G, Rimawi M et al (2005) Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56:10–20. doi:10.1007/s00280-005-0108-2 CrossRefPubMed

29.

Cheskis BJ, Greger J, Cooch N, McNally C, McLarney S, Lam H-S et al (2008) MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73:901–905. doi:10.1016/j.steroids.2007.12.028 CrossRefPubMed

Title: The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype
Authors: Hany Onsy Habashy
Desmond G. Powe
Emad A. Rakha
Graham Ball
R. Douglas Macmillan
Andrew R. Green
Ian O. Ellis
Publication date: 01-04-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0419-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women

Breast cancer-derived M543V mutation in helix 12 of estrogen receptor α inverts response to estrogen and SERMs

Predictors of interobserver agreement in breast imaging using the Breast Imaging Reporting and Data System

Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

RETRACTED ARTICLE: Late phase activation of nuclear transcription factor kappaB by doxorubicin is mediated by interleukin-8 and induction of apoptosis via FasL

Keynote webinar | Spotlight on antibody–drug conjugates in cancer